国药新冠疫苗获世卫批紧急使用 料可增至年产量30亿剂
国药集团研发的新型肺炎疫苗获世卫批准紧急使用。国药董事长杨晓明接受访问时表示,该疫苗已在全球70个国家、地区及国际组织批准注册上市或紧急使用,100多个国家及国际组织提出采购需求。他指,国药在第三阶段将扩大疫苗年产量至30亿剂,预计今年底或明年初,中国能够建立10亿人的免疫屏障。
他又称,除北京和武汉生物制品研究所,国药亦利用长春、兰州、成都、上海等生物制品所,以及国药中生生物技术研究所,持续扩大产能及分包装能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.